Comparing the current results to its competitors, 2seventy Bio Inc reported Revenue increase in the 1 quarter 2025 by 84.46 % year on year. The sales growth was above 2seventy Bio Inc 's competitors' average revenue growth of 5.05 %, achieved in the same quarter.
September 25, 2024
2seventy bio and Bristol Myers Squibb Discontinue Phase 3 KarMMa-9 Study Enrollment Amid Promising Q3 Financial Outlook CAMBRIDGE, Mass. - 2seventy bio, Inc. (Nasdaq: TSVT) recently announced a significant strategic development in collaboration with Bristol Myers Squibb (BMS). The two companies have decided to discontinue enrollment in the ongoing Phase 3 KarMMa-9 study, which examines the efficacy of Abecma (idecabtagene vicleucel; ide-cel) in combination with lenalidomide maintenance, compared to lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have had a suboptimal response to autologous stem cell transplant.The KarMMa-9 study, which aimed to investigate a pivo...
May 8, 2024
Biotechnology company 2seventy bio, Inc.’s recent financial and operational strides shed a promising light on their intensified focus on making groundbreaking cancer therapy Abecma more accessible and returning to commercial growth. This strategic realignment was reported in the company s first quarter financial results for 2024, as they continue on an upward trajectory towards financial stability while creating value for their shareholders.Headquartered in Cambridge, Massachusetts, 2seventy bio reported their Q1 results confirming a seemingly successful quarter compared to the period of the previous year. The company s CEO, Chip Baird, expressed optimism about the strategic realignment that focuses strict...
December 6, 2023
2seventy bio Reiterates Commitment to Maximizing Shareholder Value CAMBRIDGE, Mass. - In a bold move that sets the stage for future success, 2seventy bio, Inc. (NASDAQ: TSVT), a pioneering immuno-oncology cell therapy company, has reaffirmed its dedication to maximizing shareholder value. With their unwavering commitment, 2seventy is poised to revolutionize the field of cancer research and treatment. Just last month, the Board of Directors at 2seventy initiated a comprehensive process to explore all available avenues in order to maximize value. This proactive approach underscores their determination to propel the company to new heights and unlock its full potential. The process is already well underw...
Theriva Biologics Inc operates as a biotechnology company that focuses on the discovery, development, and commercialization of innovative and targeted therapies for various diseases. Their business model is centered around research and development, aiming to create new biologic drugs and bring them to the market to address unmet medical needs.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Longeveron Inc's business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Sources:
2seventy Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 2seventy Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
